Glenmark Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2289.1, down 2.48% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.15% on the day, quoting at 23542.8. The Sensex is at 75030.71, down 1.3%.Glenmark Pharmaceuticals Ltd has added around 4.38% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has increased around 8.83% in last one month and is currently quoting at 24170.45, down 0.5% on the day. The volume in the stock stood at 4.37 lakh shares today, compared to the daily average of 7.11 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 2291.4, down 2.78% on the day. Glenmark Pharmaceuticals Ltd jumped 61.5% in last one year as compared to a 4.21% slide in NIFTY and a 12.6% spurt in the Nifty Pharma index.

The PE of the stock is 44.71 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd is up for a third straight session in a row. The stock is quoting at Rs 2313.4, up 3.28% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Glenmark Pharmaceuticals Ltd has risen around 10.39% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 11.71 lakh shares today, compared to the daily average of 6.02 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 2311.1, up 3.22% on the day. Glenmark Pharmaceuticals Ltd is up 62.81% in last one year as compared to a 0.21% drop in NIFTY and a 4.48% drop in the Nifty Pharma index.

The PE of the stock is 42.64 based on TTM earnings ending December 25.

The product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

Marc Kikuchi, President & Business Head, North America said, ?At Glenmark, we remain focused on expanding access to quality and affordable medicines while continuing to strengthen our portfolio in the U.S. This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women?s healthcare.?

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25.

Shares of Glenmark Pharmaceuticals declined 1.39% to Rs 2,144.05 on the BSE.

Glenmark Pharmaceuticals (Glenmark) has received final approval from the United States Food & Drug Administration (U.S. FDA) for Progesterone Vaginal Inserts, 100 mg, determined by the FDA to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Endometrin? Vaginal Inserts, 100 mg of Ferring Pharmaceuticals Inc. [NDA 022057].

Glenmark's Progesterone Vaginal Inserts, 100 mg will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.